Author

K. N. Bobba

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

D. M. Wilson· 2 shared A. Alanizi· 1 shared A. P. Bidkar· 1 shared A. Sorlin· 1 shared A. Wadhwa· 1 shared B. Liu· 1 shared B. Nidetzky· 1 shared B. Shuere· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

D. M. Wilson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivPreprintMay 20, 2023

Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from FDG yield potent sensors of living bacteria in vivo

A. Sorlin, M. Lopez Alvarez, S. Rabbitt…·D. M. Wilson

This paper develops chemoenzymatic methods to synthesize [18F]-labeled disaccharides from FDG, which detect bacteria in vivo by their specific glycan incorporation.

DOI 10.1101/2023.05.20.541529

experimental assayhost-pathogen & immune response

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 13, 2022

Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy

A. P. Bidkar, S. Wang, K. N. Bobba…·R. R. Flavell

This study develops and evaluates [225Ac]DOTA-YS5, a radioimmunotherapy for prostate cancer, showing high efficacy in xenograft models but nephrotoxicity at higher doses.

DOI 10.1101/2022.10.13.512165

mouseproteomics

𝕏 PostBluesky